PET scan study in pulmonary hypertension related to scleroderma
Part of Heart & circulation, Lungs & breathing clinical trials.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have confirmed pulmonary hypertension linked to scleroderma (from a right-heart catheter test), based on the study’s specific definitions
- You do not smoke
- You can understand the consent form and follow study instructions
- You are not pregnant or breastfeeding
- You can lie still for a long period and you are not claustrophobic
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This study measures how much of a specific lung protein (TSPO) is present in people with pulmonary artery hypertension. The results may help researchers better understand the disease and guide future treatments.
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This study uses a special PET scan (68Ga-1A12) to look for scarring (fibrosis) in your body. The scan may help doctors see where fibrosis is happening, which could guide your treatment.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.